BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29030774)

  • 1. Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis.
    Barake M; Arabi A; Nakhoul N; El-Hajj Fuleihan G; El Ghandour S; Klibanski A; Tritos NA
    Endocrine; 2018 Jan; 59(1):39-49. PubMed ID: 29030774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender.
    Rota F; Savanelli MC; Tauchmanova L; Savastano S; Lombardi G; Colao A; Di Somma C
    J Endocrinol Invest; 2008 Feb; 31(2):94-102. PubMed ID: 18362499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study.
    Appelman-Dijkstra NM; Claessen KM; Hamdy NA; Pereira AM; Biermasz NR
    Clin Endocrinol (Oxf); 2014 Nov; 81(5):727-35. PubMed ID: 24816144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B; Kann PH
    Med Klin (Munich); 2004 Oct; 99(10):569-77. PubMed ID: 15490072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.
    Gómez JM; Gómez N; Fiter J; Soler J
    Horm Metab Res; 2000 Feb; 32(2):66-70. PubMed ID: 10741688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis.
    Barake M; Klibanski A; Tritos NA
    J Clin Endocrinol Metab; 2014 Mar; 99(3):852-60. PubMed ID: 24423364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency.
    Elbornsson M; Götherström G; Franco C; Bengtsson BÅ; Johannsson G; Svensson J
    Eur J Endocrinol; 2012 Feb; 166(2):181-9. PubMed ID: 22106341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency.
    Götherström G; Bengtsson BA; Bosaeus I; Johannsson G; Svensson J
    Eur J Endocrinol; 2007 Jan; 156(1):55-64. PubMed ID: 17218726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency.
    Elbornsson M; Götherström G; Bosæus I; Bengtsson BÅ; Johannsson G; Svensson J
    Eur J Endocrinol; 2012 May; 166(5):787-95. PubMed ID: 22318746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the growth hormone replacement on bone status in growth hormone deficient adults.
    Kužma M; Kužmová Z; Zelinková Z; Killinger Z; Vaňuga P; Lazurová I; Tomková S; Payer J
    Growth Horm IGF Res; 2014 Feb; 24(1):22-8. PubMed ID: 24382377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
    Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRABECULAR BONE SCORE CHANGE DIFFERS WITH REGARD TO 25(OH)D LEVELS IN PATIENTS TREATED FOR ADULT-ONSET GROWTH HORMONE DEFICIENCY.
    Kužma M; Binkley N; Bednárová A; Killinger Z; Vaňuga P; Payer J
    Endocr Pract; 2016 Aug; 22(8):951-8. PubMed ID: 27042750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.
    Finkenstedt G; Gasser RW; Höfle G; Watfah C; Fridrich L
    Eur J Endocrinol; 1997 Mar; 136(3):282-9. PubMed ID: 9100553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents.
    Fors H; Bjarnason R; Wirént L; Albertsson-Wikland K; Bosaeust L; Bengtsson BA; Johannsson G
    Clin Endocrinol (Oxf); 2001 Nov; 55(5):617-24. PubMed ID: 11894973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Brenckmann C; Papaioannou A
    Cochrane Database Syst Rev; 2001; (4):CD002010. PubMed ID: 11687132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Recombinant Human Growth Hormone for Osteoporosis: Systematic Review and Meta-Analysis.
    Atkinson HF; Moyer RF; Yacoub D; Coughlin D; Birmingham TB
    Can J Aging; 2017 Mar; 36(1):41-54. PubMed ID: 28069090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.